Search
Chemir Biopharmaceuticals Secures Pre-A Round Funding of Approximately 170 Million Yuan
2025-07-18 /
Read about 0 minute
Author：小编
Chemir Biopharmaceuticals (Chengdu) Co., Ltd. has recently announced the successful completion of its Pre-A round financing, raising approximately 170 million yuan. This round was led by SDIC Venture Capital, with additional investments from Star Capital, Guosheng Innovation, and existing shareholder Longpan Investment. The proceeds from this funding round will primarily be allocated towards advancing the global early clinical development of the company's core products: SN3001, a therapeutic vaccine for prostate cancer, and SN2001, an immunotherapeutic vaccine for chronic hepatitis B. Additionally, the funds will support the upgrading of the R&D center and the strategic planning for subsequent cancer therapeutic vaccine products.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
